Phibro Animal Health (PAHC) Other Non-Current Liabilities (2013 - 2026)
Phibro Animal Health (PAHC) posted Other Non-Current Liabilities of $91.5 million for Q2 2026, up 3.15% on a QoQ basis from $88.7 million in Q1 2026, and up 15.4% year-over-year from $79.3 million in Q2 2025.
Analysis
Phibro Animal Health (PAHC) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends
Phibro Animal Health has reported Other Non-Current Liabilities for 14 years, with the latest figure at $91.5 million in Q2 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 15.4% year-over-year to $91.5 million in Q2 2026; TTM through Jun 2026 was $91.5 million, a 15.4% increase from a year earlier, with the FY2026 full-year figure at $91.5 million, up 15.4% from the prior year.
- Other Non-Current Liabilities was $91.5 million for Q2 2026 at Phibro Animal Health, up from $88.7 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $91.5 million in Q2 2026, with the low at $60.3 million in Q2 2023.
- Average Other Non-Current Liabilities over 5 years is $69.4 million, with a median of $64.6 million recorded in 2022.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities declined 3.01% in 2022, then rose 25.68% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $65.1 million in 2022, then advanced by 0.35% to $65.3 million in 2023, then climbed by 4.99% to $68.6 million in 2024, then advanced by 16.98% to $80.2 million in 2025, then increased by 14.09% to $91.5 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $91.5 million (Q2 2026), $88.7 million (Q1 2026), and $80.2 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.69 Bn | 40.49 Bn | 779.09 Mn |
| 2 | Zoetis | 30.63 Bn | 28.95 Bn | 1.05 Bn |
| 3 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn |
| 4 | Phibro Animal Health | 1.49 Bn | 1.41 Bn | 134.40 Mn |
| 5 | Immucell | 90.19 Mn | 81.33 Mn | 2.44 Mn |
| 6 | Zhengye Biotechnology Holding | 76.23 Mn | 69.14 Mn | - |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 91.53 Mn |
| Mar 31, 2026 | 88.74 Mn |
| Dec 31, 2025 | 80.22 Mn |
| Sep 30, 2025 | 79.19 Mn |
| Jun 30, 2025 | 79.31 Mn |
| Mar 31, 2025 | 73.63 Mn |
| Dec 31, 2024 | 68.58 Mn |
| Sep 30, 2024 | 64.20 Mn |
| Jun 30, 2024 | 63.11 Mn |
| Mar 31, 2024 | 63.86 Mn |
| Dec 31, 2023 | 65.32 Mn |
| Sep 30, 2023 | 60.38 Mn |
| Jun 30, 2023 | 60.35 Mn |
| Mar 31, 2023 | 61.78 Mn |
| Dec 31, 2022 | 65.09 Mn |
| Sep 30, 2022 | 61.39 Mn |
| Jun 30, 2022 | 60.50 Mn |
| Mar 31, 2022 | 61.51 Mn |
| Dec 31, 2021 | 55.72 Mn |
| Sep 30, 2021 | 56.14 Mn |